Everest Medicines
PublicEverest Medicines is now publicly traded
The data on this page reflects Everest Medicines's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Oct 9, 2020
Last Round
Private Placement
Jul 25, 2025
Est. Valuation at Exit
$3.48B
Total Funding Raised
$1.22B
Company Overview
Everest Medicines is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of innovative therapies and vaccines to address critical unmet medical needs.
Sector
Healthcare
AI Layer
Application
Keywords
Everest Medicines Comparables
Compare Everest Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Oceanusbio, Inc. | 51% |
For institutional investors. Book with your work email.
Everest Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Jul 25, 2025 | ||||
| IPO | Oct 9, 2020 | ||||
| Series C | Jun 4, 2020 | ||||
| Series B | Jun 1, 2019 | ||||
| Series A | Jun 20, 2018 |
For institutional investors. Book with your work email.
Everest Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series C, Series B |
| RA Capital Management | IPO, Series C |
| Hillhouse Investment | Series C |
| Cormorant Asset Management | Series A, Series C |
| CBC Group | Private Placement, IPO, Series C, Series B, Series A |
| OrbiMed | IPO |
| GIC Private Limited | IPO |
For institutional investors. Book with your work email.
Everest Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.